Anti-vascular endothelial growth factor (VEGF) and erythropoietin therapies are used in the treatment of ROP and preterm brain injury, respectively (Patel et al., 2016; Younge et al., 2017). This evidence concerns the gene VEGFA and retinopathy of prematurity.